Microbot Medical Relocates Executive Offices
Ticker: MBOT · Form: 8-K · Filed: Jul 18, 2024 · CIK: 883975
| Field | Detail |
|---|---|
| Company | Microbot Medical Inc. (MBOT) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
Microbot Medical moved its HQ to Braintree, MA on July 18, 2024.
AI Summary
Microbot Medical Inc. filed an 8-K on July 18, 2024, to report on other events and financial statements. The filing indicates a change in the company's principal executive offices to 288 Grove Street, Suite 388, Braintree, MA 02184, effective July 18, 2024. This move from their previous Hingham, MA address is the primary event reported.
Why It Matters
A change in principal executive offices can signal operational shifts or strategic realignments within a company.
Risk Assessment
Risk Level: low — The filing solely reports a change of address for the company's principal executive offices, which is a routine administrative event.
Key Players & Entities
- Microbot Medical Inc. (company) — Registrant
- July 18, 2024 (date) — Date of earliest event reported
- 288 Grove Street, Suite 388, Braintree, MA 02184 (location) — New Principal Executive Offices
- Hingham, MA (location) — Previous Principal Executive Offices
FAQ
What is the new address for Microbot Medical Inc.'s principal executive offices?
The new address is 288 Grove Street, Suite 388, Braintree, MA 02184.
When was the change of address effective?
The change of address was effective as of July 18, 2024.
What was the previous address of Microbot Medical Inc.'s principal executive offices?
The previous address was 25 Recreation Park Dr, Suite 108, Hingham, MA 02043.
What type of filing is this 8-K?
This is a Current Report on Form 8-K, filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What are the main items reported in this 8-K?
This 8-K reports on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, with the primary event being the change in principal executive offices.
Filing Stats: 772 words · 3 min read · ~3 pages · Grade level 12.2 · Accepted 2024-07-18 08:30:37
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value MBOT NASDAQ Capital Mark
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-028281.txt ( ) — 233KB
- mbot-20240718.xsd (EX-101.SCH) — 3KB
- mbot-20240718_lab.xml (EX-101.LAB) — 33KB
- mbot-20240718_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01 of this Current Report on Form 8-K contains "forward-looking statements." Such statements which are not purely
Item 8.01 of this Current Report on Form 8-K contains "forward-looking statements." Such statements which are not purely historical (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "intends," "would," "could" and "estimates") are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company's reports and statements filed from time-to-time with the Securities and Exchange Commission. Item 9.01. Financial (d) Exhibits Exhibit Number Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MICROBOT MEDICAL INC. By: /s/ Harel Gadot Name: Harel Gadot Title: Chief Executive Officer, President and Chairman Date: July 18, 2024